Home  |  Contact

Cellosaurus Vero C1008 (CVCL_0574)

[Text version]

Cell line name Vero C1008
Synonyms VERO C1008; VeroC1008; VEROC1008; VERO C 1008; Vero 76 clone E6; Vero 76 clone E-6; Vero E-6; Vero E6; VERO E6; Vero-E6; VeroE6
Accession CVCL_0574
Resource Identification Initiative To cite this cell line use: Vero C1008 (RRID:CVCL_0574)
Comments Group: Non-human primate cell line.
Group: Vaccine production cell line.
Characteristics: Susceptible to infection by many viruses. Supports the growth of slowly replicating viruses (ATCC).
Characteristics: Susceptible to SARS coronavirus (SARS-CoV) infection (PubMed=16494729).
Characteristics: Susceptible to SARS coronavirus 2 (SARS-CoV-2) infection (COVID-19) (PubMed=32020029; PubMed=32511316).
Doubling time: 22 hours (ATCC).
Derived from sampling site: Kidney; epithelium.
Species of origin Chlorocebus sabaeus (Green monkey) (Cercopithecus sabaeus) (NCBI Taxonomy: 60711)
Hierarchy Parent: CVCL_0603 (Vero 76)
CVCL_JX48 (sVero p66)CVCL_XD71 (Vero E6-S)CVCL_YZ66 (Vero E6/NPC1-KO cl.19)
Sex of cell Female
Age at sampling Adult
Category Spontaneously immortalized cell line
Web pages https://en.wikipedia.org/wiki/Vero_cell

Earley E., Johnson K.
The lineage of Vero, Vero 76 and its clone C1008 in the United States.
(In) Vero cells: origin, properties and biomedical applications; Simizu B., Terasima T. (eds.); pp.26-29; Department of Microbiology School of Medicine Chiba University; Chiba (1988)

PubMed=16494729; DOI=10.3201/eid1201.050496
Kaye M., Druce J., Tran T., Kostecki R., Chibo D., Morris J., Catton M., Birch C.
SARS-associated coronavirus replication in cell lines.
Emerg. Infect. Dis. 12:128-133(2006)

PubMed=19016439; DOI=10.1002/9780471729259.mca04es11
Ammerman N.C., Beier-Sexton M., Azad A.F.
Growth and maintenance of Vero cell lines.
Curr. Protoc. Microbiol. 11:A.4E.1-A.4E.7(2008)

PubMed=32020029; DOI=10.1038/s41422-020-0282-0
Wang M.-L., Cao R.-Y., Zhang L.-K., Yang X.-L., Liu J., Xu M.-Y., Shi Z.-L., Hu Z.-H., Zhong W., Xiao G.-F.
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Cell Res. 30:269-271(2020)

PubMed=32511316; DOI=10.1101/2020.03.02.972935
Harcourt J., Tamin A., Lu X., Kamili S., Sakthivel S.K., Murray J., Queen K., Tao Y., Paden C.R., Zhang J., Li Y., Uehara A., Wang H., Goldsmith C., Bullock H.A., Wang L., Whitaker B., Lynch B., Gautam R., Schindewolf C., Lokugamage K.G., Scharton D., Plante J.A., Mirchandani D., Widen S.G., Narayanan K., Makino S., Ksiazek T.G., Plante K.S., Weaver S.C., Lindstrom S., Tong S., Menachery V.D., Thornburg N.J.
Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient.
bioRxiv 2020:972935-972935(2020)

Cell line collections ATCC; CRL-1586
BCRC; 60476
ECACC; 85020206
Cell line databases/resources CLDB; cl4656
CLDB; cl4657
CCRID; 3111C0001CCC000388
CCRID; 3111C0002000000097
CCRID; 3131C0001000400017
Ontologies BTO; BTO:0004755
CLO; CLO_0009527
MCCL; MCC:0000479
Gene expression databases GEO; GSM758827
GEO; GSM758828
GEO; GSM758829
GEO; GSM758830
GEO; GSM758831
GEO; GSM758832
GEO; GSM758833
GEO; GSM758834
GEO; GSM758835
GEO; GSM758836
GEO; GSM758837
GEO; GSM758838
GEO; GSM758839
GEO; GSM758840
GEO; GSM758841
GEO; GSM758842
GEO; GSM758843
GEO; GSM758844
Other Wikidata; Q54993044
Proteomic databases PRIDE; PXD018594
PRIDE; PXD018760
Entry history
Entry creation04-Apr-2012
Last entry update29-Oct-2020
Version number18